A Phase 3 interventional study of TP05 and Asacol 400 mg in Acute Ulcerative Colitis, sponsored by Tillotts Pharma AG. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-08.
Sponsored by Tillotts Pharma AG (part of Zeria Pharmaceutical) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Colitis, Ulcerative with a site in Switzerland — 10 open to participants now, 21 under way, 12 of them phase 3. Colitis, Ulcerative · Switzerland.
Among the 61 studies in Colitis, Ulcerative with a site in Switzerland, this one is the 16th largest by enrollment of the 50 interventional ones that give a count, is the only one that started in 2013, is one of 31 in phase 3, and was the 8th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →10 of the 61 studies in Colitis, Ulcerative with a site in Switzerland are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Switzerland, United States, Argentina and 30 more countries
Ages 18+
Janssen-Cilag A.G., Switzerland · Sites in Switzerland
Ages 18+
Sanofi · Sites in Switzerland, United States, Argentina and 28 more countries
Ages 16–80
Takeda · Sites in Switzerland, United States, Belgium and 11 more countries
Ages 2–17
Sanofi · Sites in Switzerland, United States, Argentina and 22 more countries
Ages 16–80
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 15 · Phase 3 34 · Phase 4 1
First in 2001; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 817 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 540 across the 50 interventional studies, 240 across the 11 observational. Of the 35 that completed or were terminated, 25 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 61 have an industry lead sponsor. The 10 most frequent:
This study is registered under Tillotts Pharma AG, one of the names counted as Zeria Pharmaceutical. Under that name alone:
Tillotts Pharma AG is the lead sponsor of 10 studies on the registry; none are open to participants now.
Zeria Pharmaceutical has 7 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
6 of the studies in Colitis, Ulcerative with a site in Switzerland that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT06029972Gilead SciencesStudy of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01 |
| NCT07012395Spyre Therapeutics, Inc.A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | 2027-06 |
| NCT05496348AbbVieStudy of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis | 2027-08 |
Add all 6 to your calendar (.ics) → With an account.
Among the 61 studies in Colitis, Ulcerative with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study was to compare the medication TP05 to the medication Asacol™ for the treatment of ulcerative colitis (UC) and to assess the safety and tolerability of TP05. This study investigated whether TP05 is as good as (non-inferior to) Asacol™(1).
(1)The trademark Asacol™ is registered in over 55 countries as Asacol™ and as Octasa™, Fivasa™, Lixacol™, Asacolon™ in the United Kingdom, France, Spain and Ireland, respectively. The rights to Asacol, including the rights to the trademark, are owned by Tillotts Pharma AG in various countries except for the following: Switzerland, USA, United Kingdom, Canada, Italy, Belgium, the Netherlands and Luxembourg.
This is a Phase 3, randomised, double-blind, active-controlled, multi-centre, non-inferiority trial evaluating the safety and efficacy of 3.2 g of TP05/day compared to 3.2 g/day of Asacol™ with an open label extension to assess the long-term safety and tolerability of TP05 administered over a 26 week period. A total of 817 subjects with mildly to moderately active UC were evaluated. Eligible subjects were randomly assigned in a 1:1 ratio to receive 3.2 g/day of TP05 (administered once daily(OD)) or 3.2 g/day of Asacol™. The primary efficacy outcome was assessed at Week 8. All subjects who respond to TP05/Asacol™ (response or remission) continued receiving blinded study treatment for up to 12 weeks. After that, subjects could enroll in an Open Label Extension (OLE) for 26 weeks duration to receive TP05. Subjects failing to respond to study drug at the Week 8 visit could enroll in the OLE at week 8 and received 4.8 g/day of TP05.
Induction phase - Main criteria for inclusion include:
Active UC defined by:
Induction Phase - Main criteria for exclusion include:
Subjects who exhibit any of the following conditions are to be excluded from the study:
(1) Severe UC defined by the following criteria: 6 bloody stools daily with one or more of the following:
c. \< 10 g/dL (2) Treatment with oral mesalamine at a dose of > 2.4 g/day within 4 weeks prior to randomisation.
(3) Treatment with topical therapy (mesalamine or ) within 2 weeks prior to randomisation (4) Treatment with systemic or rectal steroids within 4 weeks prior to randomisation.
(5) Treatment with within 6 weeks prior to randomisation. (6) Treatment with infliximab or other biologics within 3 months prior to randomisation.
(7) Treatment with antibiotics within 7 days prior to randomisation. (8) Treatment with probiotics within 7 days prior to randomisation. (9) Treatment with anti-diarrhoeal treatment within 7 days prior to randomisation.
(10) Treatment with nicotine patch within 7 days prior to randomisation. (11) Received any drug within 30 days prior to randomisation. (12) History of colectomy or partial colectomy. (13) History of definite dysplasia in colonic . (14) Crohn's disease. (15) Immediate or significant risk of toxic megacolon. (16) Known bleeding disorders. (17) to salicylates, aspirin, sulfasalazine or mesalazine. (18) Serum creatinine > 1.5 times the . (19) (AST), alanine aminotransferase (ALT), total or alkaline phosphatase > 2 times the upper limit of the normal range.
(20) Serious underlying disease other than UC which in the opinion of the investigator may interfere with the subject's ability to fully participate in the study.
(21) History of alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures.
(22) Stools positive for Clostridium difficile toxin. (23) Pregnant or lactating women. (24) Prior enrolment in the study.
OLE - Main criteria for inclusion include:
OLE - Main criteria for exclusion include:
(1) Withdrawal from the induction phase prior to the Week 8 visit.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
week 1 - week 12 (blinded), week 13 - week 38 (OpenLabel)
Drug: TP05
week 1 - week 12 (blinded), switch to TP05 for weeks 13-38 (open label)
Drug: Asacol 400 mg
3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)
Also known as: Mesalazine 1600 mg
3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)
Also known as: Mesalazine (Tillotts Pharma AG)
Period 1: Clinical and Endoscopic Remission
Mayo Score of \<= 2 points with no individual sub-score \> 1
Time frame: Week 8
Period 2: Clinical Response, Open-Label Extended Induction
A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.
Time frame: Week 16
Period 3: Clinical Remission
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)
Time frame: Week 38
Period 1: Endoscopic Remission
Endoscopic remission was defined as a Mayo endoscopy subscore of 0
Time frame: Week 8
Period 1: Endoscopic Response
Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one.
Time frame: Week 8
Period 1: Clinical Remission
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)
Time frame: Week 8
Period 1: Rectal Bleeding Sub-score of 0
Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score
Time frame: Week 8
Period 1: Clinical and Endoscopic Response
Clinical and Endoscopic Response was defined as a decrease in the Mayo score of ≥3 points from baseline and a reduction of ≥ 30% from baseline with either an accompanying decrease in the rectal bleeding sub-score of at least 1 point or an absolute rectal bleeding sub-score of 0 or 1 at the Week 8 visit. If a subject withdrew from the study prior to Week 8 or their response status was not evaluable due to incomplete and/or invalid data, the subject was considered a non-responder.
Time frame: Week 8
Period 1: Clinical Remission
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)
Time frame: Week 12
Period 1: Clinical Response
A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.
Time frame: Week 12
Period 1: Rectal Bleeding Score of 0
Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score
Time frame: Week 12
Period 1: Clinical Remission at Both Week 8 and 12
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)
Time frame: Week 8 and week 12
Period 1: Clinical Response at Both Week 8 and Week 12
A decrease in the Partial Mayo Score of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.
Time frame: Week 8 and Week 12
Period 1: Change in Mayo Score From Baseline
Between-Group Difference of Mayo Score, Change from Baseline The changes from baseline to week 8 values in Mayo scores are compared between the two treatment groups. The Mayo scoring system is a well-established tool for assessing UC disease activity. The Mayo score is the sum of 4 component sub-scores, each scored on a scale ranging from 0 representing no pathology to 3 for severe disease. The 4 component sub-scores consist of, 1) stool frequency, 2) rectal bleeding, 3) flexible sigmoidoscopy scores, and 4) physician's global assessment. A Mayo score of 0 indicates no pathology and a score of 12, severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Mayo score from baseline when patients experienced acute disease, indicates improvement and treatment success.
Time frame: Baseline and Week 8
Period 1: Change in Partial Mayo Score From Baseline
Between-Group Difference of Partial Mayo Score, Change from Baseline to Week 8 The Partial Mayo Score is the sum of the component sub-scores, 1) stool frequency, 2) rectal bleeding and 3) physician's global assessment. A partial Mayo Score of 0 indicates no disease and a maximum score of 9 indicates severe symptoms. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Partial Mayo Score from Baseline where patients experienced acute disease, indicates improvement and treatment success.
Time frame: Baseline and Week 8
Period 1: Change in Stool Frequency Score
Between-Group Difference of Stool Frequency Score, Change from Baseline The changes from baseline to week 8 values in stool frequency will be compared between the two treatment groups. Values for stool frequency range between 0 and 3. A value of 0 indicates normal stool frequency, a value of 3 indicates 5 or more stools than normal. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between week 8 values and baselines indicates treatment success.
Time frame: Baseline and Week 8
Period 1: Change in Rectal Bleeding Score From Baseline
Between-Group Difference of Rectal Bleeding Score, Change from Baseline The changes from baseline to week 8 values in rectal bleeding scores will be compared between the two treatment groups. A value of 0 indicates no rectal bleeding, a value of 3 indicates only blood is passing. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference at week 8 compared to baseline is indicative of treatment success.
Time frame: Baseline and Week 8
Period 1: Change in Physician Global Assessment Score From Baseline
Between-Group Difference of Physician Global Assessment Score, Change from Baseline. The changes from baseline to week 8 values in the Physician Global Assessment score will be compared between the two treatment groups. A value of 0 means no pathology and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success.
Time frame: Baseline and Week 8
Period 1: Change in Endoscopic Score From Baseline
Between-Group Difference of Endoscopic Score, Change from Baseline. The changes from baseline to week 8 values in sigmoidoscopic (mucosal) appearance scores will be compared between the two treatment groups. A value of 0 in the endoscopic score means normal or inactive disease and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success.
Time frame: Baseline and Week 8
Period 2: Clinical Remission
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)
Time frame: Week 16
Period 2: Rectal Bleeding Sub-score of 0
Percentage of patients achieving the endpoint rectal bleeding sub-score of 0
Time frame: Week 16
Period 2: Stool Frequency 0
Percentage of patients achieving the endpoint stool frequency sub-score of 0
Time frame: Week 16
Period 2: Urgency
Percentage of patients achieving an Urgency Score of 0. A score of 0 indicates no urgency reported in any of the three days prior to the visit at week 16. A score of 1 indicates urgency reported in any of the three days prior to the visits.
Time frame: Week 16
Period 2: UC-Related Complications
Percentage of Patients Experiencing Complications related to UC
Time frame: Week 16
Period 3: Clinical Response
A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.
Time frame: Week 38
Period 3: Clinical and Endoscopic Remission
Mayo Score of \<= 2 points with no individual sub-score \> 1
Time frame: Week 38
Period 3: Clinical and Endoscopic Response
Both has to be achieved, Clinical and Endoscopic Response which is defined by a decrease from baseline in the Mayo score of ≥ 3 points and \> 30% of the baseline score, with an accompanying decrease in the rectal bleeding sub-score of ≥ 1 point or an absolute rectal bleeding sub-score of 0 or 1.
Time frame: Week 38
Period 3: Endoscopic Remission
Percentage of each dose group achieving an endoscopy sub score of 0
Time frame: Week 38
Period 3: Endoscopic Response
Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one.
Time frame: Week 38
Period 3: Rectal Bleeding Sub Score of 0
Percentage of each dose group achieving the endpoint rectal bleeding subscore 0
Time frame: Week 38
Period 3: Stool Frequency Sub-score 0
Patients achieving a Stool Frequency sub-score of 0
Time frame: Week 38
Period 3: No Urgency
No urgency is a score of 0 and indicates that patients did not report urgency during any of the three days prior to the visit at week 38. A score of 1 indicates that urgency was reported during any of these three days.
Time frame: Week 38
Period 3: UC-Related Complications
Percentage of Patients with Complications related to UC
Time frame: Week 38
| Milestone | TP05 (Mesalazine) 1600 mg | Asacol (Mesalazine 400 mg) | Extended Induction | 1.6g TP05 (1600 mg) /Day Maintenance Open-Label | 3.2g TP05 (1600 mg) /Day Maintenance Open-Label | 4.8g TP05 (1600 mg) /Day Maintenance Open-Label |
|---|---|---|---|---|---|---|
| Started | 409 | 408 | 0 | 0 | 0 | 0 |
| Completed | 370 | 367 | 0 | 0 | 0 | 0 |
| Not completed | 39 | 41 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 20 | 18 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 10 | 13 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 2 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance, | 7 | 7 | 0 | 0 | 0 | 0 |
| Milestone | TP05 (Mesalazine) 1600 mg | Asacol (Mesalazine 400 mg) | Extended Induction | 1.6g TP05 (1600 mg) /Day Maintenance Open-Label | 3.2g TP05 (1600 mg) /Day Maintenance Open-Label | 4.8g TP05 (1600 mg) /Day Maintenance Open-Label |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 243 | 0 | 0 | 0 |
| Completed | 0 | 0 | 220 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 23 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 17 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 5 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | TP05 (Mesalazine) 1600 mg | Asacol (Mesalazine 400 mg) | Extended Induction | 1.6g TP05 (1600 mg) /Day Maintenance Open-Label | 3.2g TP05 (1600 mg) /Day Maintenance Open-Label | 4.8g TP05 (1600 mg) /Day Maintenance Open-Label |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 202 | 274 | 199 |
| Completed | 0 | 0 | 0 | 196 | 253 | 181 |
| Not completed | 0 | 0 | 0 | 6 | 21 | 18 |
| Withdrew: Adverse event | 0 | 0 | 0 | 3 | 9 | 14 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 6 | 2 |
| Withdrew: Other | 0 | 0 | 0 | 2 | 6 | 2 |
Mayo Score of \<= 2 points with no individual sub-score \> 1
| Participants | TP05 (Mesalazine) | Asacol (Mesalazine, Tillotts Pharma AG) |
|---|---|---|
| Period 1: Clinical and Endoscopic Remission | 87 | 95 |
A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.
| Participants | Extended Induction |
|---|---|
| Period 2: Clinical Response, Open-Label Extended Induction | 183 |
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)
| percentage of participant | 1.6g/Day Maintenance Open-Label | 3.2/Day Maintenance Open-Label | 4.8g/Day Maintenance Open-Label |
|---|---|---|---|
| Period 3: Clinical Remission | 70.3 | 33.9 | 30.7 |
Endoscopic remission was defined as a Mayo endoscopy subscore of 0
| Participants | TP05 (Mesalazine) | Asacol (Mesalazine, Tillotts Pharma AG) |
|---|---|---|
| Period 1: Endoscopic Remission | 36 | 44 |
Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one.
| Participants | TP05 (Mesalazine) | Asacol (Mesalazine, Tillotts Pharma AG) |
|---|---|---|
| Period 1: Endoscopic Response | 185 | 196 |
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)
| Participants | TP05 (Mesalazine) | Asacol (Mesalazine, Tillotts Pharma AG) |
|---|---|---|
| Period 1: Clinical Remission | 92 | 110 |
Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score
| Participants | TP05 (Mesalazine) | Asacol (Mesalazine, Tillotts Pharma AG) |
|---|---|---|
| Period 1: Rectal Bleeding Sub-score of 0 | 212 | 226 |
Clinical and Endoscopic Response was defined as a decrease in the Mayo score of ≥3 points from baseline and a reduction of ≥ 30% from baseline with either an accompanying decrease in the rectal bleeding sub-score of at least 1 point or an absolute rectal bleeding sub-score of 0 or 1 at the Week 8 visit. If a subject withdrew from the study prior to Week 8 or their response status was not evaluable due to incomplete and/or invalid data, the subject was considered a non-responder.
| Participants | TP05 (Mesalazine) | Asacol (Mesalazine) |
|---|---|---|
| Period 1: Clinical and Endoscopic Response | 221 | 236 |
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)
| Participants | TP05 (Mesalazine) | Asacol (Mesalazine, Tillotts Pharma AG) |
|---|---|---|
| Period 1: Clinical Remission | 93 | 113 |
A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.
| Participants | TP05 (Mesalazine) | Asacol (Mesalazine, Tillotts Pharma AG) |
|---|---|---|
| Period 1: Clinical Response | 223 | 233 |
Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score
| Participants | TP05 (Mesalazine) | Asacol (Mesalazine, Tillotts Pharma AG) |
|---|---|---|
| Period 1: Rectal Bleeding Score of 0 | 193 | 205 |
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)
| Participants | TP05 (Mesalazine) | Asacol (Mesalazine, Tillotts Pharma AG) |
|---|---|---|
| Period 1: Clinical Remission at Both Week 8 and 12 | 66 | 80 |
A decrease in the Partial Mayo Score of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.
| Participants | TP05 (Mesalazine) | Asacol (Mesalazine, Tillotts Pharma AG) |
|---|---|---|
| Period 1: Clinical Response at Both Week 8 and Week 12 | 216 | 230 |
Between-Group Difference of Mayo Score, Change from Baseline The changes from baseline to week 8 values in Mayo scores are compared between the two treatment groups. The Mayo scoring system is a well-established tool for assessing UC disease activity. The Mayo score is the sum of 4 component sub-scores, each scored on a scale ranging from 0 representing no pathology to 3 for severe disease. The 4 component sub-scores consist of, 1) stool frequency, 2) rectal bleeding, 3) flexible sigmoidoscopy scores, and 4) physician's global assessment. A Mayo score of 0 indicates no pathology and a score of 12, severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Mayo score from baseline when patients experienced acute disease, indicates improvement and treatment success.
| units on a scale | TP05 (Mesalazine) | Asacol (Mesalazine) |
|---|---|---|
| Period 1: Change in Mayo Score From Baseline | 3.1 ± 2.7 | 3.2 ± 2.6 |
Between-Group Difference of Partial Mayo Score, Change from Baseline to Week 8 The Partial Mayo Score is the sum of the component sub-scores, 1) stool frequency, 2) rectal bleeding and 3) physician's global assessment. A partial Mayo Score of 0 indicates no disease and a maximum score of 9 indicates severe symptoms. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Partial Mayo Score from Baseline where patients experienced acute disease, indicates improvement and treatment success.
| units on a scale | TP05 (Mesalazine) | Asacol (Mesalazine) |
|---|---|---|
| Period 1: Change in Partial Mayo Score From Baseline | 2.5 ± 2.2 | 2.5 ± 2.2 |
Between-Group Difference of Stool Frequency Score, Change from Baseline The changes from baseline to week 8 values in stool frequency will be compared between the two treatment groups. Values for stool frequency range between 0 and 3. A value of 0 indicates normal stool frequency, a value of 3 indicates 5 or more stools than normal. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between week 8 values and baselines indicates treatment success.
| units on a scale | TP05 (Mesalazine) | Asacol (Mesalazine) |
|---|---|---|
| Period 1: Change in Stool Frequency Score | 0.9 ± 1.1 | 0.9 ± 1.1 |
Between-Group Difference of Rectal Bleeding Score, Change from Baseline The changes from baseline to week 8 values in rectal bleeding scores will be compared between the two treatment groups. A value of 0 indicates no rectal bleeding, a value of 3 indicates only blood is passing. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference at week 8 compared to baseline is indicative of treatment success.
| units on a scale | TP05 (Mesalazine) | Asacol (Mesalazine) |
|---|---|---|
| Period 1: Change in Rectal Bleeding Score From Baseline | 0.9 ± 0.8 | 1.0 ± 0.8 |
Between-Group Difference of Physician Global Assessment Score, Change from Baseline. The changes from baseline to week 8 values in the Physician Global Assessment score will be compared between the two treatment groups. A value of 0 means no pathology and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success.
| units on a scale | TP05 (Mesalazine) | Asacol (Mesalazine) |
|---|---|---|
| Period 1: Change in Physician Global Assessment Score From Baseline | 0.6 ± 0.8 | 0.7 ± 0.8 |
Between-Group Difference of Endoscopic Score, Change from Baseline. The changes from baseline to week 8 values in sigmoidoscopic (mucosal) appearance scores will be compared between the two treatment groups. A value of 0 in the endoscopic score means normal or inactive disease and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success.
| units on a scale | TP05 (Mesalazine) | Asacol (Mesalazine) |
|---|---|---|
| Period 1: Change in Endoscopic Score From Baseline | 0.5 ± 0.9 | 0.6 ± 0.8 |
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)
| Participants | Extended Induction |
|---|---|
| Period 2: Clinical Remission | 53 |
Percentage of patients achieving the endpoint rectal bleeding sub-score of 0
| Participants | Extended Induction |
|---|---|
| Period 2: Rectal Bleeding Sub-score of 0 | 146 |
Percentage of patients achieving the endpoint stool frequency sub-score of 0
| Participants | Extended Induction |
|---|---|
| Period 2: Stool Frequency 0 | 64 |
Percentage of patients achieving an Urgency Score of 0. A score of 0 indicates no urgency reported in any of the three days prior to the visit at week 16. A score of 1 indicates urgency reported in any of the three days prior to the visits.
| Participants | Extended Induction |
|---|---|
| Period 2: Urgency | 109 |
Percentage of Patients Experiencing Complications related to UC
| Participants | Extended Induction |
|---|---|
| Period 2: UC-Related Complications | 0.0 |
A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.
| percentage of participants | 1.6g/Day Maintenance Open-Label | 3.2/Day Maintenance Open-Label | 4.8g/Day Maintenance Open-Label |
|---|---|---|---|
| Period 3: Clinical Response | 94.1 | 83.9 | 78.4 |
Mayo Score of \<= 2 points with no individual sub-score \> 1
| percentage of participants | 1.6g/Day Maintenance Open-Label | 3.2/Day Maintenance Open-Label | 4.8g/Day Maintenance Open-Label |
|---|---|---|---|
| Period 3: Clinical and Endoscopic Remission | 65.8 | 39.4 | 29.6 |
Both has to be achieved, Clinical and Endoscopic Response which is defined by a decrease from baseline in the Mayo score of ≥ 3 points and \> 30% of the baseline score, with an accompanying decrease in the rectal bleeding sub-score of ≥ 1 point or an absolute rectal bleeding sub-score of 0 or 1.
| percentage of participants | 1.6g/Day Maintenance Open-Label | 3.2/Day Maintenance Open-Label | 4.8g/Day Maintenance Open-Label |
|---|---|---|---|
| Period 3: Clinical and Endoscopic Response | 89.6 | 78.1 | 69.3 |
Percentage of each dose group achieving an endoscopy sub score of 0
| percentage of participants | 1.6g/Day Maintenance Open-Label | 3.2/Day Maintenance Open-Label | 4.8g/Day Maintenance Open-Label |
|---|---|---|---|
| Period 3: Endoscopic Remission | 37.6 | 32.4 | 13.6 |
Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one.
| percentage of participants | 1.6g/Day Maintenance Open-Label | 3.2/Day Maintenance Open-Label | 4.8g/Day Maintenance Open-Label |
|---|---|---|---|
| Period 3: Endoscopic Response | 73.8 | 58.8 | 53.3 |
Percentage of each dose group achieving the endpoint rectal bleeding subscore 0
| percentage of participants | 1.6g/Day Maintenance Open-Label | 3.2/Day Maintenance Open-Label | 4.8g/Day Maintenance Open-Label |
|---|---|---|---|
| Period 3: Rectal Bleeding Sub Score of 0 | 88.1 | 76.3 | 74.9 |
Patients achieving a Stool Frequency sub-score of 0
| Participants | 1.6g/Day Maintenance Open-Label | 3.2/Day Maintenance Open-Label | 4.8g/Day Maintenance Open-Label |
|---|---|---|---|
| Period 3: Stool Frequency Sub-score 0 | 148 | 101 | 66 |
No urgency is a score of 0 and indicates that patients did not report urgency during any of the three days prior to the visit at week 38. A score of 1 indicates that urgency was reported during any of these three days.
| Participants | 1.6g/Day Maintenance Open-Label | 3.2/Day Maintenance Open-Label | 4.8g/Day Maintenance Open-Label |
|---|---|---|---|
| Period 3: No Urgency | 161 | 173 | 109 |
Percentage of Patients with Complications related to UC
| Participants | 1.6g/Day Maintenance Open-Label | 3.2/Day Maintenance Open-Label | 4.8g/Day Maintenance Open-Label |
|---|---|---|---|
| Period 3: UC-Related Complications | 3 | 2 | 1 |
Collected over 2 years, 11 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TP05/TP05 | — | 24/409 (5.9%) | 58/409 (14.2%) |
| Asacol/TP05 | — | 18/408 (4.4%) | 75/408 (18.4%) |
| TP05 Extended Induction | — | 3/243 (1.2%) | 0/243 (0%) |
| TP05 | — | 9/409 (2.2%) | 26/409 (6.4%) |
| Asacol | — | 7/408 (1.7%) | 22/408 (5.4%) |
| Event | TP05/TP05 | Asacol/TP05 | TP05 Extended Induction | TP05 | Asacol |
|---|---|---|---|---|---|
| Deterioration ulcerative colitiesGastrointestinal disorders | 9/409 | 6/408 | 0/243 | 4/409 | 4/408 |
| AnaemiaBlood and lymphatic system disorders | 2/409 | 2/408 | 0/243 | 1/409 | 1/408 |
| DepressionPsychiatric disorders | 0/409 | 2/408 | 0/243 | 0/409 | 0/408 |
| Hypertensive heart diseaseCardiac disorders | 1/409 | 0/408 | 1/243 | 0/409 | 0/408 |
| Artrial fibrilationCardiac disorders | 1/409 | 0/408 | 1/243 | 0/409 | 0/408 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/409 | 1/408 | 1/243 | 0/409 | 0/408 |
| PneumoniaInfections and infestations | 1/409 | 1/408 | 0/243 | 1/409 | 1/408 |
| Cerebral infarctionNervous system disorders | 0/409 | 1/408 | 0/243 | 0/409 | 0/408 |
| Cerebral haematomaNervous system disorders | 0/409 | 1/408 | 0/243 | 0/409 | 0/408 |
| Herniated discMusculoskeletal and connective tissue disorders | 0/409 | 1/408 | 0/243 | 0/409 | 0/408 |
| Event | TP05/TP05 | Asacol/TP05 | TP05 Extended Induction | TP05 | Asacol |
|---|---|---|---|---|---|
| Worsening of UCGastrointestinal disorders | 58/409 | 75/408 | 0/243 | 26/409 | 22/408 |
Safety Population (SAF)/Intent to Treat (ITT)
| Age, Continuous(years) | TP05 (Mesalazine) | Asacol (Mesalazine, Tillotts Pharma AG) | Total |
|---|---|---|---|
| Mean | 43.97 ± 14.54 | 43.3 ± 14.11 | 43.5 ± 14.32 |
| Sex: Female, Male(Participants) | TP05 (Mesalazine) | Asacol (Mesalazine, Tillotts Pharma AG) | Total |
|---|---|---|---|
| Female | 171 | 178 | 349 |
| Male | 238 | 230 | 468 |
| Race/Ethnicity, Customized(Participants) | TP05 (Mesalazine) | Asacol (Mesalazine, Tillotts Pharma AG) | Total |
|---|---|---|---|
| White | 378 | 386 | 764 |
| Black | 1 | 1 | 2 |
| Asian or Pacific Islander | 7 | 3 | 10 |
| Mixed/Other | 0 | 1 | 1 |
| Not Available | 23 | 17 | 40 |
| Region of Enrollment(participants) | TP05 (Mesalazine) | Asacol (Mesalazine, Tillotts Pharma AG) | Total |
|---|---|---|---|
| Belarus | 47 | 49 | 96 |
| Belgium | 9 | 8 | 17 |
| Bulgaria | 15 | 15 | 30 |
| Canada | 15 | 17 | 32 |
| Czech Republic | 20 | 18 | 38 |
| Denmark | 20 | 16 | 36 |
| Finland | 2 | 1 | 3 |
| Hungary | 17 | 11 | 28 |
| France | 23 | 16 | 39 |
| Ireland | 1 | 0 | 1 |
| Latvia | 22 | 22 | 44 |
| Lithuania | 26 | 28 | 54 |
| Norway | 4 | 5 | 9 |
| Poland | 44 | 48 | 92 |
| Romania | 2 | 1 | 3 |
| Russian Federation | 51 | 50 | 101 |
| Serbia | 18 | 18 | 36 |
| Slovakia | 2 | 3 | 5 |
| Spain | 0 | 2 | 2 |
| Sweden | 1 | 2 | 3 |
| Ukraine | 59 | 71 | 130 |
| United Kingdom | 11 | 7 | 18 |
| Mayo Score(units on a scale) | TP05 (Mesalazine) | Asacol (Mesalazine, Tillotts Pharma AG) | Total |
|---|---|---|---|
| Mean | 7.7 ± 1.3 | 7.6 ± 1.3 | 7.7 ± 1.3 |
| Partial Mayo Clinic Score(units on a scale) | TP05 (Mesalazine) | Asacol (Mesalazine, Tillotts Pharma AG) | Total |
|---|---|---|---|
| Mean | 5.5 ± 1.1 | 5.3 ± 1.1 | 5.4 ± 1.1 |
Plan to share: No
Ran from Jul 2013 to primary completion in May 2016, 34 months.
Results were first posted in Aug 2018, 2 years 3 months after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 34 months is below that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.